Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Akụkọ

Ihe ịma aka dị na ịgwọ ọrịa ero na-awakpo nke ukwuu n'ime ndị ọrịa hematologic cancer: nghọta sitere na ASH 2024

Ihe ịma aka dị na ịgwọ ọrịa ero na-awakpo nke ukwuu n'ime ndị ọrịa hematologic cancer: nghọta sitere na ASH 2024

2025-01-03

Na Nzukọ Kwa Afọ nke ASH nke afọ 2024, Prọfesọ Sun Yuqian kesara nnyocha ọhụrụ ya gbasara ọrịa fungal nke na-awakpo ebilite (bIFD) n'ahụ ndị ọrịa nwere ọrịa hematologic, na-akọwapụta ihe ịma aka nchọpụta na ọgwụgwọ, yana nghọta bara uru dabere na ọmụmụ ihe ndị e mere n'oge na-adịbeghị anya.

lee nkọwa zuru ezu
Ọganihu na Nhazi Ihe Ize Ndụ T-ALL: Nhazi nke NGS na-achọpụta otu ndị nwere ihe egwu dị elu

Ọganihu na Nhazi Ihe Ize Ndụ T-ALL: Nhazi nke NGS na-achọpụta otu ndị nwere ihe egwu dị elu

2025-01-03

Ọmụmụ ihe ọhụrụ e bipụtara na Ọbara na-emeziwanye nhazi ihe egwu maka ọrịa leukemia lymphoblastic acute T-cell (T-ALL) site na iji usoro ọgbọ na-esote (NGS), na-eme ka amụma amụma dịkwuo mma ma na-achọpụta obere ndị nwere ike irite uru na ọgwụgwọ ezubere iche.

lee nkọwa zuru ezu
Ijikwa Nsogbu Ogologo Oge nke Ọgwụgwọ CAR-T: Nghọta sitere na Ọrịa Kansa Okike

Ijikwa Nsogbu Ogologo Oge nke Ọgwụgwọ CAR-T: Nghọta sitere na Ọrịa Kansa Okike

2024-12-25

Nnyocha e bipụtara n'oge na-adịbeghị anya na Ọrịa Kansa Okike na-akọwapụta nsogbu ogologo oge nke ọgwụgwọ mkpụrụ ndụ CAR-T, na-elekwasị anya n'ihe egwu nke ọrịa na ọrịa kansa nke abụọ, ma na-enye atụmatụ iji mee ka nsonaazụ ndị ọrịa ka mma.

lee nkọwa zuru ezu
Ihe Mmụta Ọhụrụ | Ndị otu ahụike Lu Daopei bipụtara ọmụmụ ihe dị mkpa na British Journal of Hematology

Ihe Mmụta Ọhụrụ | Ndị otu ahụike Lu Daopei bipụtara ọmụmụ ihe dị mkpa na British Journal of Hematology

2024-12-23

Ndị otu ahụike Lu Daopei, nke Dr. Cao Xingyu na Prọfesọ Lu Peihua na-edu, ebipụtala akwụkwọ nyocha ahụike dị mkpa na Akwụkwọ akụkọ Britain nke Hematology (Impact Factor 5.1). Ọmụmụ ihe a na-enyocha nchekwa na irè nke mgbanwe mkpụrụ ndụ hematopoietic (allo-HSCT) mgbe ọgwụgwọ autologous CD7 CAR-T maka T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (R/R T-ALL/T-LBL) nke na-adịghị agbanwe agbanwe ma na-alaghachi azụ.

lee nkọwa zuru ezu
Akụkọ Onye Ọrịa | Ọrịa Leukemia Myeloid Dị Ike (AML-M2) Onye Lanarịrị: Afọ 9 Mgbe A Gwụsịrị Ya, Nakwere Ike nke Olileanya na Mmụgharị

Akụkọ Onye Ọrịa | Ọrịa Leukemia Myeloid Dị Ike (AML-M2) Onye Lanarịrị: Afọ 9 Mgbe A Gwụsịrị Ya, Nakwere Ike nke Olileanya na Mmụgharị

2024-12-23

Akụkọ na-akpali akpali sitere n'ụlọ ọgwụ Lu Daopei, na-akọwa njem nke nwoke dị afọ 32 lanarịrị AML-M2, onye, ​​mgbe e mechara mgbanwe mkpụrụ ndụ haploidical, na-eme emume afọ 9 nke mgbaghara, na-ebi ndụ zuru oke ma na-akpali akpali, nke ịhụnanya, olileanya, na ntachi obi na-akwalite.

lee nkọwa zuru ezu
Ọnụọgụ Nlanarị Ka Mma site na Bu/Cy+Melphalan na Bu/Cy+Thiotepa Regimens na Haploidentical Stem Cell Transplantation maka Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL)

Ọnụọgụ Nlanarị Ka Mma site na Bu/Cy+Melphalan na Bu/Cy+Thiotepa Regimens na Haploidentical Stem Cell Transplantation maka Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL)

2024-12-17

Nnyocha e mere na ASH 2024 site n'aka Dr. Zhi-Jie Wei na ndị otu ya na Lu Daopei Hospital na-egosi irè nke usoro Bu/Cy gbanwere na haploidentical hematopoietic stem transplantation maka Non-Down Syndrome Acute Megakaryoblastic Leukemia (AMKL), na-egosi nsonaazụ ndụ dị mma maka ndị ọrịa mgbaghara zuru oke (CR).

lee nkọwa zuru ezu
Nsonaazụ Ndị Na-ekwe Nkwa Maka Ọgwụgwọ CD7 CAR-T n'Ịgwọ Lymphoma T-Cell Peripheral Relapsed/Refractory na ASH 2024

Nsonaazụ Ndị Na-ekwe Nkwa Maka Ọgwụgwọ CD7 CAR-T n'Ịgwọ Lymphoma T-Cell Peripheral Relapsed/Refractory na ASH 2024

2024-12-17

Na Nzukọ Kwa Afọ nke ASH nke afọ 2024, Prọfesọ Lu Peihua si n'ụlọ ọgwụ Lu Daopei gosipụtara ihe dị ịtụnanya sitere na nnwale Phase I nke ọgwụgwọ mkpụrụ ndụ CD7 CAR-T maka lymphoma T-cell nke na-alaghachi azụ/na-adịghị ike (R/R PTCL), nke na-egosi irè na nchekwa a na-achịkwa nke ọma.

lee nkọwa zuru ezu
Imeri ihe ịma aka na ọgwụgwọ CAR-T maka ọrịa kansa ọbara T-cell

Imeri ihe ịma aka na ọgwụgwọ CAR-T maka ọrịa kansa ọbara T-cell

2024-12-11

Ọ bụ ezie na ọgwụgwọ CAR-T agbanweela ọgwụgwọ nke kansa mkpụrụ ndụ B, mana nnukwu ihe ịma aka ka dị n'ịgwọ ọrịa kansa mkpụrụ ndụ T. Nyocha e mere n'oge na-adịbeghị anya na-enyocha mgbagwoju anya nke ọgwụgwọ CAR-T na ọrịa kansa mkpụrụ ndụ T na ihe ngwọta nwere ike isi merie ihe mgbochi ndị a.

lee nkọwa zuru ezu
Ọganihu na Ọgwụgwọ Mbụ maka Ndị Okenye B-ALL: Nyocha zuru oke sitere na The Lancet Hematology

Ọganihu na Ọgwụgwọ Mbụ maka Ndị Okenye B-ALL: Nyocha zuru oke sitere na The Lancet Hematology

2024-12-09

Nyocha ọhụrụ na Ọgwụ ọbara Lancet na-egosi ọganihu dị ukwuu n'ọgwụgwọ mbụ nke ndị okenye ọhụrụ a chọpụtara ọhụrụ B-cell Lymphoblastic Leukemia (B-ALL), na-elekwasị anya n'ụzọ ọgwụgwọ ahaziri ahazi, ọgwụgwọ immunotherapy ọhụrụ, na nsonaazụ ndị ọrịa ka mma.

lee nkọwa zuru ezu
Nwa okorobịa nwetara olileanya mgbe achọpụtachara AML M4a Njem nke iguzogide na mgbake

Nwa okorobịa nwetara olileanya mgbe achọpụtachara AML M4a Njem nke iguzogide na mgbake

2024-12-05

Mgbe ọ lụsịrị ọrịa leukemia myeloid dị nkọ (AML-M4a) ma mee mgbanwe mkpụrụ ndụ stem dị ndụ, otu onye ọrịa na-eto eto chọtara olileanya, ahụike, na mmalite ọhụrụ, site na nlekọta pụrụ iche nke ụlọ ọgwụ Lu Daopei.

lee nkọwa zuru ezu
Ọganihu Ọhụrụ na Ọgwụgwọ na Nchọpụta Ọrịa Lymphoma (PCNSL) Sistemụ Nrụgide Isi nke Isi

Ọganihu Ọhụrụ na Ọgwụgwọ na Nchọpụta Ọrịa Lymphoma (PCNSL) Sistemụ Nrụgide Isi nke Isi

2024-12-04

Ọganihu ọhụrụ a na-enwe n'ịchọpụta na ịgwọ ọrịa nke Primary Central Nervous System Lymphoma (PCNSL) enyela ndị ọrịa olileanya ọhụrụ. Nyocha ọhụrụ sitere na Mahadum Stanford na-egosi mkpa ọ dị ịchọpụta ọrịa n'oge na nhọrọ ọgwụgwọ kachasị ọhụrụ, gụnyere chemotherapy na ọgwụgwọ ezubere iche.

lee nkọwa zuru ezu
Akụkọ Onye Ọrịa: Imeri Ọrịa Leukemia Myeloid Dị Ike na Ịmụghachi Ọmụmụ Mgbe E Dozichara Mkpụrụ Ndụ

Akụkọ Onye Ọrịa: Imeri Ọrịa Leukemia Myeloid Dị Ike na Ịmụghachi Ọmụmụ Mgbe E Dozichara Mkpụrụ Ndụ

2024-12-03

Otu nwoke dị afọ iri atọ na anọ, onye ọrịa, na-ekerịta njem ya na-akpali akpali nke ịlụso ọrịa leukemia myeloid acute (AML) ọgụ, na-anata ọtụtụ usoro ọgwụgwọ chemotherapy na mgbanwe mkpụrụ ndụ stem cell, na-eme emume afọ atọ nke mgbake na olileanya ọhụrụ.

lee nkọwa zuru ezu